Trial Profile
A Pilot Phase II Study of Neoadjuvant Fulvestrant Plus Abemaciclib in Women With Advanced Low Grade Serous Carcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 31 Jul 2023
Price :
$35
*
At a glance
- Drugs Abemaciclib (Primary) ; Fulvestrant (Primary)
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 25 Jul 2023 Planned End Date changed from 30 Sep 2025 to 30 Sep 2024.
- 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 05 May 2022 Planned End Date changed from 1 May 2022 to 30 Sep 2025.